Regulatory effects of deguelin on proliferation and cell cycle of Raji cells

Abstract

The underlying mechanism of deguelin regulating the cell cycle in human Burkitt’s lymphoma cell line Raji cells in vitro, and the cytotoxicity of deguelin to Raji cells and human peripheral blood monocular cells (PBMCs) were investigated. The effects of deguelin on the growth of Raji cells were studied by 3-(4, 5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium (MTT) assay. Apoptosis was detected through Hoechst 33258 staining. The effect of deguelin on the cell cycle of Raji cells was studied by a propidium iodide method. The expression levels of cyclin D1, P21 and pRb were examined by using Western blotting. The results showed that the proliferation of Raji cells was inhibited in the deguelin-treated group, with a 24-h IC₅₀ value of 21.61 nmol/L and a 36-h IC₅₀ value of 17.07 nmol/L. Proliferation in Raji cells was inhibited significantly by deguelin, while little change was observed in PBMCs. Deguelin induced G₂/M arrest in Raji cells. The expression of cyclin D1, P21 and pRb was dramatically down-regulated by deguelin in a dose-dependent manner. It was concluded that deguelin could inhibit the proliferation of Raji cells by arresting the cells at G2/M phase and inducing the cell apoptosis. Moreover, deguelin selectively induced apoptosis of Raji cells with low toxicity to PBMCs. The antitumor effects of deguelin were related to the down-regulated expression of cyclin D1, P21 and pRb proteins.

Keywords

deguelin / cell cycle / apoptosis / Burkitt’s lymphoma

References

[1] ChunKH, KosmederJW2nd, SunS, et al.. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst, 2003, 95(4): 291-302

[2] UdeaniGO, ZhaoGM, ShinYG, et al.. Pharmacokinetics of deguelin, a cancer chemopreventive agent in rats. Cancer Chemother Pharmacol, 2001, 47(3): 263-268

[3] IzevbigieEB, BryantJL, WalkerA. A novel natural inhibitor of extracellular signal-regulated kinases and human breast cancer cell growth. Exp Biol Med, 2004, 229(2): 163-169

[4] VoseJM, LinkBK, GrossbardML, et al.. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma, 2005, 46(11): 1569-1573

[5] LiuHL, ChenY, CuiGH, et al.. Deguelin regulates nuclear pore complex proteins Nup98 and Nup88 in U937 cells in vitro. Acta Pharmacol Sin, 2005, 26(10): 1265-1273

[6] UdeaniGO, GerhauserC, ThomasCF, et al.. Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid. Cancer Res, 1997, 57(16): 3424-3428

[7] LeeHY, SuhYA, KosmederJW, et al.. Deguelin-induced inhibition of cyclooxygenase-2 expression in human bronchial epithelial cells. Clin Cancer Res, 2004, 10(3): 1074-1079

[8] HailNJ, LotanR. Apoptosis induction by the natural product cancer chemopreventive agent deguelin is mediated through the inhibition of mitochondrial bioenergetics. Apoptosis, 2004, 9(4): 437-447

[9] LiZ, WuJ, WuC, et al.. Deguelin, a natural rotenoid, inhibits mouse myeloma cell growth in vitro via induction of apoptosis. Oncol Lett, 2012, 4(4): 677-681

[10] EvanGI, VousdenKH. Proliferation, cell cycle and apoptosis in cancer. Nature, 2001, 411(6835): 342-348

[11] PietenpolJA, StewartZA. Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. Toxicology, 2002, 181–182: 475-481

[12] OrmerodMG. Investigating the relationship between the cell cycle and apoptosis using flow cytometry. J Immunol Methods, 2002, 265(1–2): 73-80

[13] BortulR, TazzariPL, BilliAM, et al.. Deguelin, a PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway. Br J Haematol, 2005, 129(5): 677-686

[14] SuhYA, KimJH, SungMA, et al.. A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer. Cancer Lett, 2013, 332(1): 102-109

[15] ThamilselvanV, MenonM, ThamilselvanS A. nticancer efficacy of deguelin in human prostate cancer cells targeting glycogen synthase kinase-3 β/β-catenin pathway. Int J Cancer, 2011, 129(12): 2916-2927

[16] LiuHL, ChenY, CuiGH, et al.. Regulating expressions of cyclin D1, pRb, and anti-cancer effects of deguelin on human Burkittos lymphoma Daudi cells in vitro. Acta Pharmacol Sin, 2005, 26(7): 873-880

[17] DworakowskaD, JassemE, JassemJ, et al.. Prognostic value of cyclin D1 overexpression in correlation with pRb and p53 status in non-small cell lung cancer (NSCLC). J Cancer Res Clin Oncol, 2005, 131(7): 479-485

[18] JiBC, YuCC, YangST, et al.. Induction of DNA damage by deguelin is mediated through reducing DNA repair genes in human non-small cell lung cancer NCI-H460 cells. Oncol Rep, 2012, 27(4): 959-964